J&J adds yet an­oth­er mul­ti­ple myelo­ma reg­i­men to the Darza­lex la­bel as Sanofi ri­val jumps in

J&J’s third-line mul­ti­ple myelo­ma block­buster Darza­lex got the FDA green light for a new reg­i­men to take an­oth­er swing at the blood can­cer — this time, in a cock­tail with carfil­zomib and dex­am­etha­sone.

The com­bi­na­tion ther­a­py was ap­proved to treat re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma pa­tients who have al­ready re­ceived one to three lines of treat­ment.

Darza­lex, a CD38-di­rect­ed an­ti­body, led the mar­ket for years af­ter its ap­proval in 2015 for third-line mul­ti­ple myelo­ma pa­tients. But this year, it faces com­pe­ti­tion from Sanofi’s Sar­clisa, an­oth­er CD38-tar­get­ing drug ap­proved in April as a third-line treat­ment for mul­ti­ple myelo­ma pa­tients, in com­bi­na­tion with po­ma­lido­mide and dex­am­etha­sone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER